Catalyst Pharmaceuticals

Yahoo Finance • 6 days ago

Catalyst raises 2025 revenue guidance to $565M–$585M while launching $200M share buyback program

Earnings Call Insights: Catalyst Pharmaceuticals (CPRX) Q3 2025 MANAGEMENT VIEW * Richard John Daly, President and CEO, stated that "Catalyst delivered outstanding third quarter 2025 results with accelerating momentum, strong demand fo... Full story

Yahoo Finance • 7 days ago

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Reported Q3 2025 Total Revenues of $148.4Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Mi... Full story

Yahoo Finance • 8 days ago

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 9 days ago

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference

CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 21 days ago

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • last month

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for pe... Full story

Yahoo Finance • last month

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel med... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investing Opportunity with Strong Fundamentals

The practice of value investing centers on identifying companies trading below their intrinsic worth, a strategy pioneered by Benjamin Graham and later refined by investors like Warren Buffett. This approach emphasizes purchasing securitie... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Investment with Strong Growth and Reasonable Valuation

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX [https://www.chartmill.com/stock/quote/CPRX]) has appeared as a noteworthy candidate for investors using a Growth At Reasonable Price (GARP) strategy, which looks for companies showing strong growt... Full story

Yahoo Finance • 2 months ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a High-Quality Caviar Cruise Candidate

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX [https://www.chartmill.com/stock/quote/CPRX]) has appeared as a notable candidate via the Caviar Cruise stock screening method, a systematic process made to find high-quality companies suitable for... Full story

Yahoo Finance • 3 months ago

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 3 months ago

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel... Full story

Yahoo Finance • 3 months ago

Catalyst Pharmaceuticals settles lawsuit with Lupin

[law legal] utah778/iStock via Getty Images Catalyst Pharmaceuticals (NASDAQ:CPRX [https://seekingalpha.com/symbol/CPRX]) said that the company and licensor SERB S.A. signed a settlement agreement with Lupin Pharmaceuticals, putting an en... Full story

Yahoo Finance • 3 months ago

Catalyst settles patent dispute with Lupin over FIRDAPSE

CORAL GABLES, Fla. - Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), a $2.58 billion market cap biopharmaceutical company with an impressive 83% gross profit margin, announced Monday it has reached a settlement agreement with Lupin Ltd and L... Full story

Yahoo Finance • 3 months ago

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel me... Full story

Yahoo Finance • 3 months ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Value Investment in Biotech

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX [https://www.chartmill.com/stock/quote/CPRX]) presents a strong case for value investors looking for chances in the biotechnology sector. The company was found using a screening method that focuses... Full story

Yahoo Finance • 3 months ago

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Top Affordable Growth Stock with Strong Fundamentals

Investors looking for growth opportunities at fair prices often consider the "Affordable Growth" strategy, which finds companies with good growth prospects, steady profits, and strong finances, all while trading at reasonable prices. This... Full story

Yahoo Finance • 3 months ago

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaf... Full story

Yahoo Finance • 3 months ago

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a supportive care treatmentGuideline inclusion may raise clinical awareness of cancer-associated LEMS to support broader... Full story

Yahoo Finance • 3 months ago

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished... Full story